Special Issue

Metabolomics in the Study of Disease

Message from the Guest Editor

Metabolomics can be used to investigate complex diseases that affect modern society including diabetes, dementia, heart disease, and cancer. Such diseases are often associated with, and characterised by, genetic mutations, but downstream metabolic consequences are not always well understood. Metabolomics has the potential to elucidate changes in cellular metabolism that may not be predictable from genetics but that present a cellular phenotype where therapeutic interventions can have selective and targeted effects. New metabolomics methods and applications, which help us gain insight into the complexities of the disease metabolome, are of particular relevence. In this Special Issue of *Metabolites*, we will demonstrate current developments and applications for diagnosis. understanding mechanisms, and finding new treatments for disease.


Guest Editor

Prof. Dr. James McCullagh

Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford OX13TA, UK

Deadline for manuscript submissions

closed (30 August 2019)



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/22863

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

